The global lung transplant therapeutics market is witnessing significant growth, driven by the increasing prevalence of end-stage lung diseases, advancements in transplant techniques, and a growing focus on improving post-transplant outcomes. Lung transplantation is a life-saving treatment option for patients with severe lung diseases such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and cystic fibrosis.
Key factors contributing to market growth include the rising incidence of lung diseases, an aging population, and an increase in awareness about lung transplantation as a viable treatment option. In addition, technological advancements in organ preservation, immunosuppression, and post-transplant care are enhancing the success rates of lung transplant procedures, driving market growth. Key players in the global lung transplant therapeutics market are focusing on developing novel therapeutics and improving existing treatment options to enhance patient outcomes. These companies are also engaging in strategic collaborations, partnerships, and acquisitions to expand their product portfolios and geographical presence, further driving market growth.
The Global Lung Transplant Therapeutics Market size is projected to reach USD 218.10 million by 2031, with a CAGR of 4.8% during the forecast period of 2024 to 2031.
To know more, visit https://www.databridgemarketresearch.com/jp/reports/global-lung-transplant-therapeutics-market
Below are the Top Five Lung Transplant Therapeutics Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Astellas Pharma Inc.
|
Astellas is a key player, offering immunosuppressant drugs such as Prograf (tacrolimus) and Advagraf (modified-release tacrolimus) that are commonly used to prevent organ rejection in lung transplant recipients. Astellas's commitment to improving patient outcomes and advancing transplant medicine underscores its leadership in the field of lung transplant therapeutics.
|
|
North America, Europe, South America, Asia- Pacific
|
In April 2021, Astellas Pharma Inc. received “2021 Award for Excellence in Corporate Disclosure” from the Securities Analysts Association of Japan. This helped company in strengthening its position over the market, gaining more customer base.
|
|
2.
|
TransMedics
|
TransMedics is a prominent player in the global lung transplant therapeutics market, offering the Organ Care System (OCS), a portable perfusion device that maintains donor lungs in a near-physiological state during transport and allows for assessment and optimization of lung function prior to transplantation. TransMedics's innovative approach to organ preservation is revolutionizing lung transplantation and improving outcomes for transplant recipients.
|
|
North America
|
In July 2021, TransMedics had obtained the FDA approval for the OCS Lung Solution used for the cold preservation of lungs. The FDA approval received would result in improvement in product portfolio or organ preservation, and it would meet the unmet clinical needs of the organ transplant market. It would ensure collaborations with market players to supply and meet the customer needs for lung transplantation.
|
|
3.
|
Dr. Reddy’s Laboratories Ltd.
|
Dr. Reddy's Laboratories offers a range of generic immunosuppressant drugs that are used in lung transplant recipients to prevent organ rejection. The company's focus on affordability and accessibility of medications makes it a significant player in providing essential therapeutics for lung transplant patients worldwide.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In October 2014, Dr. Reddy's Laboratories announced the launch of Sirolimus Tablets 1 mg and 2 mg, a generic version of RAPAMUNE (Sirolimus) tablets, in the US market. This launch followed approval by the United States Food & Drug Administration (USFDA). The RAPAMUNE® tablets brand had U.S. sales of approximately $206 million MAT for the most recent twelve months ending in August 2014, according to IMS Health.
|
|
4.
|
F. Hoffmann-La Roche Ltd.
|
In the global lung transplant therapeutics market, Roche offers immunosuppressant drugs such as CellCept (mycophenolate mofetil) and Valcyte (valganciclovir), which are used in lung transplant recipients to prevent organ rejection and treat viral infections. Roche's commitment to advancing medical science and improving patient care positions it as a key player in lung transplant therapeutics.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In April 2024, Roche's Alecensa received FDA approval as the first adjuvant treatment for individuals with ALK-positive early-stage lung cancer. This approval was based on the Phase III ALINA study, which demonstrated that Alecensa reduced the risk of disease recurrence or death by a remarkable 76% in individuals with ALK-positive early-stage resected non-small cell lung cancer (NSCLC).
|
|
5.
|
Hikma Pharmaceuticals PLC
|
Hikma Pharmaceuticals offers a range of immunosuppressant drugs used in lung transplant recipients to prevent organ rejection. The company's focus on quality, affordability, and accessibility of medications makes it a significant contributor to lung transplant therapeutics globally.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In January 2022, Hikma Pharmaceuticals PLC expanded in Canada with acquisition of Teligent sterile injectable assets which includes a portfolio of 25 sterile injectable products, three in-licensed ophthalmic products and a pipeline of seven additional products, four of which are approved by Health Canada. This portfolio of exciting products will enable company to expand North American business and develop a solid position in this important market.
|
Conclusion
The global lung transplant therapeutics market is experiencing significant growth, driven by factors such as the increasing prevalence of end-stage lung diseases, advancements in transplant techniques, and a growing focus on improving post-transplant outcomes. Key players such as Astellas Pharma Inc., TransMedics, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., and Hikma Pharmaceuticals PLC are at the forefront of this market, offering a range of innovative therapies and technologies to enhance patient outcomes. The market is characterized by ongoing research and development efforts aimed at improving the efficacy and safety of lung transplant procedures. In addition, strategic collaborations, partnerships, and acquisitions are common strategies among key players to expand their product portfolios and geographical presence, further driving market growth.
